Samuel I. Miller
Dr. Miller holds a B.A. from Johns Hopkins University and a M.D. from Baylor College of Medicine. Dr. Miller is a former faculty member of the Harvard Medical School. In addition to his Microbiology Department appointment, he is a Professor in the Department of Medicine, Division of Allergy and Infectious Diseases, and in the Department of Genome Sciences. He is an Adjunct Professor of Immunology. He is a past Director of a Research Center of Excellence in Biodefense and Emerging Infectious Diseases for the region and Director of the Cystic Fibrosis Research and Development Program at the University of Washington.
The lab is organized into research groups focusing on the study of:
1) Salmonellae translocated effectors (which are delivered across the phagosome membrane and function to modify host processes by binding host GTPases, and acting as glycerol-cholesterol acyltransferases and ubiquitin ligases.
2) Bioinformatic analysis, DNA sequencing and phenotypic comparison of Shigella and Salmonella outbreak strains from diverse geographic locations including Central America and Africa and specifically the emergence of non-typhoidal Salmonella strains in Africa.
3) The environmental remodeling of the gram-negative bacterial envelope that occurs when bacteria infect host tissues and specifically the regulated alteration of glycerolphospholipids in the bacterial outer membrane by using a combination of bacterial genetics and mass spectrometry analysis of lipids.
4) Using NMR and crystallography to define structural mechanisms by which PhoQ responds to antimicrobial peptides and low pH and specifically testing the hypothesis that signal transduction involves the loss of structure on one side of the membrane with specific gain of structure on the other side of the membrane.
5) Identification of human genome polymorphisms that alter susceptibility to bacterial infection and diversity of human immune responses by using the human cellular genome wide association study (GWAS) platform using bacteria and the HapMap cell collection of normal human diversity.
6) How the bacterial second messenger di-c-GMP controls cellular processes and use of a FRET based biosensor for c-di-GMP to understand bacterial cellular function and diversity, and development of compounds that alter human interferon signaling by competing with mammalian molecules that bind cyclic nucleotides.
7) Human studies that involve analysis of the microbiota. The diseases analyzed using a metagenomic approach and DNA sequencing include inflammatory bowl disease and cystic fibrosis, as well as stool transplantation.
Recent Publications from PubMed
- Karalewitz AP, Miller SIAntimicrobial agents and chemotherapy. 2018 Jun; :
- Adaptation of commensal proliferating to the intestinal tract of young children with cystic fibrosis.Matamouros S, Hayden HS, Hager KR, Brittnacher MJ, Lachance K, Weiss EJ, Pope CE, Imhaus AF, McNally CP, Borenstein E, Hoffman LR, Miller SIProceedings of the National Academy of Sciences of the United States of America. 2018 Feb; 115 7: 1605-1610
- Miller SI, Salama NRPLoS biology. 2018 Jan; 16 1: e2004935
- Akullian A, Montgomery JM, John-Stewart G, Miller SI, Hayden HS, Radey MC, Hager KR, Verani JR, Ochieng JB, Juma J, Katieno J, Fields B, Bigogo G, Audi A, Walson JPLoS neglected tropical diseases. 2018 01; 12 1: e0006156
- Transition from early intervention program to primary school in children with autism spectrum disorder.Eapen V, Grove R, Aylward E, Joosten AV, Miller SI, Van Der Watt G, Fordyce K, Dissanayake C, Maya J, Tucker M, DeBlasio AWorld journal of clinical pediatrics. 2017 Nov; 6 4: 169-175